Allogeneic stem cell transplantation 1 article

At the center of allogeneic stem cell transplantation is donor hematopoietic stem cells, supported by allogeneic HSCT and HLA matching. Those features establish it as a donor-derived hematopoietic cell transplantation and connect the entity to graft-versus-host disease, graft-versus-leukemia effect and donor stem cell engraftment; an additional biological or analytical context is bone marrow transplantation. Its boundaries are set by cell source, engineering status and immune mechanism, which distinguish allogeneic stem cell transplantation from neighboring adoptive-cell and transplantation approaches.

Clinical Trials & Evidence

September 19, 2026, 1:18 AM · 3 mins read

Arovella Therapeutics gets FDA clearance to start first human trial of ALA-101 cell therapy

Arovella Therapeutics has received FDA clearance to begin Phase 1 clinical testing of its allogeneic cell therapy ALA-101 targeting CD19-positive blood cancers.